Use of simple noninvasive biomarkers to predict liver fibrosis in HIV/HCV coinfection in routine clinical practice

HIV Medicine

Volumn 11, Issue 7, 2010, Pages 439-447

  Macias J ^a   Gonzalez J ^b   Ortega, E ^c   Tural, C ^d   Cabrero, E ^e   Burgos, A ^e   Pineda, J A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e ABBOTT LABORATORIES   (Spain)

Author keywords

Aspartate aminotransferase to platelet ratio index (APRI); Forns index; HIV HCV coinfection; Liver biopsy; Liver fibrosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NON INVASIVE PROCEDURE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL ANALYSIS; THROMBOCYTE;

ADULT; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; CROSS-SECTIONAL STUDIES; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 77955150206     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00812.x     Document Type: Article

References (22)

1. Pineda JA, García-García JA, Aguilar-Guisado M. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007, 46:622-630.
2. Alberti A, Clumeck N, Collins S. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615-624.
3. Nelson M, Matthews G, Brook MG, Main J. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis C virus infection (2005). HIV Med 2005, 6((Suppl 2)):96-106. for the BHIVA Coinfection Guideline Committee; British HIV Association.
4. Aranzabal L, Casado JL, Moya J. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005, 40:588-593.
5. Mira JA, Macías J, Girón-González JA. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2006, 58:140-146.
6. Labarga P, Soriano V, Vispo ME. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196:670-676.
7. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
8. Rousselet MC, Michalak S, Dupre F. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005, 41:257-264.
9. Macías J, Girón-González JA, González-Serrano M. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006, 55:409-414.
10. Tural C, Tor J, Sanvisens A. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009, 7:339-345.
11. Nunes D, Fleming C, Offner G. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005, 40:538-544.
12. Cacoub P, Carrat F, Bédossa P. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: the fibrovic study-ANRS HC02. J Hepatol 2008, 48:765-773.
13. Loko MA, Castera L, Dabis F. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008, 103:1973-1980.
14. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005, 6:375-378.
15. Trang T, Petersen JR, Snyder N. Non-invasive markers of hepatic fibrosis in patients co-infected with HCV and HIV: comparison of the APRI and FIB-4 index. Clin Chim Acta 2008, 397:51-54.
16. Carvalho-Filho RJ, Schiavon LL, Narciso-Schiavon JL. Optimized cutoffs improve performance of the aspartate aminotransferase to platelet ratio index for predicting significant liver fibrosis in human immunodeficiency virus/hepatitis C virus co-infection. Liver Int 2008, 28:486-493.
17. Kelleher TB, Mehta SH, Bhaskar R. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005, 43:78-84.
18. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology 2002, 123:1367-1384.
19. Irwig L, Bossuyt P, Glasziou P, Gatsonis C, Lijmer J. Designing studies to ensure that estimates of test accuracy are transferable. BMJ 2002, 324:669-667.
20. Tural C, Ortega E, Pineda JA, González-García J, Burgos A, Cabrero E. Cross-sectional study to determine prevalence of significant liver fibrosis (F2-F4) in HIV-HCV coinfected patients. GRAFIHCO study. Glasgow, UK, November 2008 [Abstract P264]
21. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994, 20:15-20. The French METAVIR Cooperative Study Group.
22. Poynard T, Munteanu M, Imbert-Bismut F. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004, 50:1344-1355.